Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-The example of isavuconazole.
Beveridge healthcare system
antifungal treatment
invasive aspergillosis
invasive fungal diseases
invasive mucormycosis
isavuconazole
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
04
06
2021
received:
28
04
2021
accepted:
07
06
2021
pubmed:
17
6
2021
medline:
7
1
2022
entrez:
16
6
2021
Statut:
ppublish
Résumé
Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck-based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge-based healthcare systems. The aim of this study was to evaluate the market access process and reimbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England and Spain. Market access processes of both countries were described. Focussing on typical patient clusters for isavuconazole treatment, reimbursement data regarding inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid leukaemia was considered. Data were publicly available and of high topicality (England 2020/2021, Spain 2018). Discounting and a currency conversion to Euro were applied. This study showed that market access processes of both countries are broadly similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may lead to reduction in resource utilisation. Without medication costs, isavuconazole can thus result in cost savings for both patient clusters due to a reduction in length of stay. Expenses for innovative pharmaceuticals may be balanced or even lead to cost savings due to a reduction in length of stay. The latter contributes to a greater patient benefit. For both healthcare system, the analyses highlighted drugs' cost-effectiveness and assessing its added value into reimbursement decisions is highly relevant.
Sections du résumé
BACKGROUND
BACKGROUND
Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck-based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge-based healthcare systems.
OBJECTIVES
OBJECTIVE
The aim of this study was to evaluate the market access process and reimbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England and Spain.
PATIENTS/METHODS
METHODS
Market access processes of both countries were described. Focussing on typical patient clusters for isavuconazole treatment, reimbursement data regarding inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid leukaemia was considered. Data were publicly available and of high topicality (England 2020/2021, Spain 2018). Discounting and a currency conversion to Euro were applied.
RESULTS
RESULTS
This study showed that market access processes of both countries are broadly similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may lead to reduction in resource utilisation. Without medication costs, isavuconazole can thus result in cost savings for both patient clusters due to a reduction in length of stay.
CONCLUSIONS
CONCLUSIONS
Expenses for innovative pharmaceuticals may be balanced or even lead to cost savings due to a reduction in length of stay. The latter contributes to a greater patient benefit. For both healthcare system, the analyses highlighted drugs' cost-effectiveness and assessing its added value into reimbursement decisions is highly relevant.
Substances chimiques
Antifungal Agents
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1213-1222Subventions
Organisme : Pfizer
Informations de copyright
© 2021 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
Enoch D, Ludlam H, Brown N. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55(Pt 7):809-818.
Bajpai V, Khan I, Shukla S, et al. Invasive fungal infections and their epidemiology: measures in the clinical scenario. Biotechnol Bioprocess Eng. 2019;24:436-444.
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26.
Erjavec Z, Kluin-Nelemans H, Verweij P. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect. 2009;15(7):625-633.
Cornely O, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;9(12):e405-21.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-e38.
van der Zee J, Kroneman M. Bismarck or Beveridge: a beauty contest between dinosaurs. BMC Health Serv Res. 2007;7:94.
Health Expenditure Per Capita. Health at a Glance 2019: OECD Indicators; 2019. https://www.oecd-ilibrary.org/sites/876d99c3-en/index.html?itemId=/content/component/876d99c3-en. Accessed December 01, 2020.
Kron F, Wingen-Heimann S, Jeck J, Lazzaro C, Cornely O, Thielscher C. Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals. Mycoses. 2021;64(1):86-94.
Lameire N, Joffe P, Wiedemann M. Healthcare systems-an international review: an overview. Nephrol Dial Transplant. 1999;14(Suppl_6):3-9.
Jantunen E, Anttila VJ, Ruutu T. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress? Bone Marrow Transplant. 2002;30(12):925-929.
Caira M, Girmenia C, Fadda RM, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol. 2008;81(3):242-243.
Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068-1075.
Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644-650.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760-769.
General Methods Version - 6.0 of 05.11.2020. 2020; Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). https://www.iqwig.de/methoden/allgemeine-methoden_version-6-0.pdf?rev=180500. Accessed March 24, 2021.
von der Schulenburg J-M, Greiner W, Jost F, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11(4):539-544.
Annex DtA: The national tariff workbook, 2020/21. 2020; National Health Service Improvement. https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/. Accessed April 15, 2021.
A guide to the market forces factor - A joint publication by NHS England and NHS Improvement. 2019; National Health Service Improvement / National Health Service England. https://improvement.nhs.uk/documents/4995/1920_Guide__to_MFF.pdf. Accessed March 24, 2021.
WÄHRUNGSRECHNER: BRITISCHE PFUND - EURO (GBP IN EUR). https://www.finanzen.net/waehrungsrechner/britische-pfund_euro. Accessed December 1, 2020.
Blueteq established as the system for High Cost Drugs Management Process in NHS England's Commissioning Intentions 2016/2017!. Blueteq Ltd. http://www.blueteq.com/latestnews/ArticleID/2/Blueteq-established-as-the-system-for-High-Cost-Drugs-Management-Process-in-NHS-Englands-Commissioning-Intentions-2016-2017. Accessed December 01, 2020.
Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal. 2018; Ministerio de Sanidad, Consumo y Bienestar Social. https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbd.htm. Accessed December 01, 2020.
About CCGs. National Health Service Clinical Commissioners (NHSCC). https://www.nhscc.org/ccgs/. Accessed December 01, 2020.
Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics. 2014;32(5):509-520.
Weidlich D, Hicks M, Floros L, Patel J, Charbonneau C, Sung A. Pin18-estimating the budget and clinical impact of introducing isavuconazole for the treatment of patients with possible invasive Aspergillosis in the United Kingdom. Value Health. 2018;21:S223-S224.
Floros L, Pagliuca A, Taie AA, et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. J Med Econ. 2020;23(1):86-97.
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access - Chapters and Glossary. 2018; Department of Health & Social Care / Association of the British Pharmaceutical Industry. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf. Accessed March 23, 2021.
Specialised Services. National Health Service England. https://www.england.nhs.uk/commissioning/spec-services/. Accessed January 18, 2021.
High cost drugs. 2012; GOV.UK. https://www.gov.uk/government/news/high-cost-drugs--2. Accessed March 23, 2021.
Contracts and payment guidance October 2020 - March 2021. 2020; National Health Service. https://www.england.nhs.uk/wp-content/uploads/2020/09/C0768-finance-guidance-with-annex-3-added-23-september-2020-.pdf Accessed March 24, 2021.
Single Technology Appraisal - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [ID1508] / Committee Papers. 2019; National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta640/evidence/appraisal-consultation-committee-papers-pdf-8828294941. Accessed March 24, 2021.
FICHA TECNICA CRESEMBA 100mg capsulas duras. Agencia espanola de medicamentos y productos sanitarios / Centro de información de medicamentos. https://cima.aemps.es/cima/dochtml/ft/1151036002/FT_1151036002.html. Accessed March 24, 2021.
FICHA TECNICA CRESEMBA 200mg polvo para concentrado para solucion para perfusion. Agencia espanola de medicamentos y productos sanitarios / Centro de información de medicamentos. https://cima.aemps.es/cima/dochtml/ft/1151036001/FT_1151036001.html. Accessed March 24, 2021.
Oliva-Moreno J, Puig-Junoy J, Trapero-Bertran M, Epstein D, Pinyol C, Sacristán J. Economic evaluation for pricing and reimbursement of new drugs in spain: fable or desideratum? Value Health. 2020;23(1):25-31.
Funciones Dirección General de Cartera Básica de Servicios del Sistema Nacional de Salud y Farmacia. Ministerio de Sanidad, Consumo y Bienestar Social. https://www.mscbs.gob.es/organizacion/ministerio/organizacion/sgralsanidad/dgcbssnsyfF.htm. Accessed March 23, 2021.
Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público; Capítulo V, Artículo 8. 2010; BOE-A-2010-8228; Boletin Oficial del Estado - Legislacion Consolidada. https://www.boe.es/buscar/pdf/2010/BOE-A-2010-8228-consolidado.pdf. Accessed March 24, 2020.
Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público; Capítulo V, Artículo 9. 2010; BOE-A-2010-8228; Boletin Oficial del Estado - Legislacion Consolidada. https://www.boe.es/buscar/pdf/2010/BOE-A-2010-8228-consolidado.pdf. Accessed March 24, 2021.
Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público; Capítulo V, Artículo 10. 2010; BOE-A-2010-8228; Boletin Oficial del Estado - Legislacion Consolidada. https://www.boe.es/buscar/pdf/2010/BOE-A-2010-8228-consolidado.pdf. Accessed March 24, 2021.
Pinyol C, Calvente N, Espinosa C, Gilabert T, Carlos M (from the ISPOR Regional Spain Chapter). Market access in Spain. In: Güvenç Koçkaya AW, ed. Pharmaceutical Market Access in Developed Markets. Turin: SEEd Medical Publishers; 2018:77-98.
Geissler A, Scheller-Kreinsen D, Quentin W, Busse R. DRG-systeme in Europa. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz. 2012;55(5):633-642.
Expert Panel on effective ways of investing in Health (EXPH). Innovative payment models for high-cost innovative medicines. Health; 2018. https://ec.europa.eu/health/sites/health/files/expert_panel/docs/opinion_innovative_medicines_en.pdf. Accessed March 24, 2021.
Morrison E, Webb D. UK Health Technology Assessment and value based pricing. In: Babar Z, ed. Pharmaceutical Prices in the 21st Century. Switzerland: Springer International Publishing; 2015:371-388.
Hurst L, Mahtani K, Pluddemann A, et al. Defining value-based healthcare in the NHS: The CEBM Report. Centre for Evidence-Based Medicine. 2019.
Current healthcare expenditure relative to GDP, 2017. 2020; Eurostat - Statistics Explained; 2017. https://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_expenditure_statistics Accessed December 01, 2020.